Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|August 14, 2024

Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

Author(s)Lawrence Karsh, MD, FACS, Stephen J. Freedland, MD, Terence Friedlander, MD

The panel outlines combination therapy options for patients with advanced prostate cancer and discusses the potential benefits of intensification of androgen deprivation therapy.

Episodes in this series

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 1 Prostate Cancer Treatment: The Evolving Therapeutic Landscape

Stephen Freedland, MD, an expert on prostate cancer

EP. 2 The Heterogeneity of Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 3 The Role of ADT in Localized or Locally Advanced Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 4 EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 5 Treatment Considerations in Nonmetastatic CSPC

Terence Friedlander, MD, an expert on prostate cancer

EP. 6 Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 7 Treatment Options in Castration-Resistant Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 8 The Relationship Between Prostate Cancer and Cardiovascular Disease

Stephen Freedland, MD, an expert on prostate cancer

EP. 9 Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 10 ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Dual AR blockade shows promise for treatment-naïve mHSPC

ByHannah Clarke

February 13th 2026

MDT associated with prolonged PFS in oligometastatic prostate cancer

ByHannah Clarke

February 12th 2026

Oxybutynin superior to placebo in reducing ADT-associated hot flashes

ByHannah Clarke

February 11th 2026

National Cancer Prevention Month: Prostate Cancer Screening FAQs for Clinicians

ByHannah Clarke

February 10th 2026

URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues

ByHannah Clarke

February 4th 2026

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Trending on Urology Times

FDA approves label changes for first batch of menopausal hormone therapy products

Urologist explains science behind HA penile injections

Dual AR blockade shows promise for treatment-naïve mHSPC

Pearls & Perspectives: Expanding Options in Male Incontinence, with Laura Horodyski, MD

Pearls & Perspectives: Elevating Survivorship in Urologic Care, with Bruce R. Kava, MD